1
|
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns. Ann Dermatol Venereol 2024; 151:103243. [PMID: 38325268 DOI: 10.1016/j.annder.2023.103243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 09/05/2023] [Indexed: 02/09/2024]
|
2
|
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study. J Eur Acad Dermatol Venereol 2021; 35:e511-e514. [PMID: 33783881 DOI: 10.1111/jdv.17253] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
3
|
Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Syndrome de relargage cytokinique induit par le cémiplimab : premier cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
|
6
|
Analyse en vie réelle de la technique du ganglion sentinelle dans la prise en charge du mélanome primitif dans un centre d’onco-dermatologie. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Pustulose palmoplantaire unilatérale sous avélumab. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
|
9
|
Un kyste peut en cacher un autre. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2019.05.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Anti‐
PD
1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature. J Eur Acad Dermatol Venereol 2018; 33:e159-e161. [DOI: 10.1111/jdv.15352] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Translocation bactérienne sur dysbiose intestinale sous thérapie ciblée : description d’un cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Analyse des connaissances et du ressenti d’une l’équipe de dermatologie concernant l’hypnose thérapeutique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Tatouage sous immunothérapie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
First case of trastuzumab emtansine-associated hemorrhagic telangiectasias treated with propranolol. Dermatol Ther 2018; 32:e12756. [PMID: 30285315 DOI: 10.1111/dth.12756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 09/20/2018] [Accepted: 09/29/2018] [Indexed: 11/27/2022]
|
15
|
Abstract
PURPOSE The dermatological toxicity of cancer treatments is frequent and sometimes debilitating. Its reference classification, the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events), is sometimes difficult to use and does not include yet the newest toxicities. Our objective was to create a guide, TOXICAN, based on the CTCAE, which is easy to use in everyday practice and which facilitates the recognition and grading of these dermatological toxicities. METHODS This guide was developed by a working group ("GESTIM") comprising oncodermatologists, allergists, pathologists, and researchers from Nantes University Hospital. It was based on the dermatological toxicities found in the CTCAE and adapted to daily practice. These toxicities were grouped into categories and associated with photographs of typical cases to aid recognition. A simplified grading scale derived from the CTCAE was also created. This booklet was validated by means of user evaluation, and then the Delphi consensus method. RESULTS We selected 32 dermatological toxicities, including 12 created by our group, sorted into 7 categories: skin rash, dry skin/pruritus, hyperkeratotic papules, palmoplantar changes, hair and nail changes, mucosal changes, and others. Our simplified grading scale only differed from the CTCAE for one item, urticaria. Three items were modified after evaluation by the user group and 11 after application of the Delphi method. CONCLUSION The objective of our practical guide is to facilitate the use of the CTCAE for recognizing and grading dermatological toxicity of cancer treatments in order to provide optimal guidance for therapeutic adaptations. Its impact on clinical practice remains to be evaluated.
Collapse
|
16
|
Pneumopathie organisée associée à une granulomatose sarcoïdose-like survenue sous nivolumab. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Biomarqueurs prédictifs sanguins de bonne réponse au nivolumab dans le mélanome avancé : une cohorte rétrospective. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Photosensibilité aux UVA sous thérapie ciblée combinée par vémurafénib et cobimétinib. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Combinaison propranolol et cyclophosphamide dans l’angiosarcome : à propos de deux cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy. J Eur Acad Dermatol Venereol 2017; 32:e104-e106. [PMID: 28865162 DOI: 10.1111/jdv.14579] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
21
|
Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas? J Eur Acad Dermatol Venereol 2017; 32:e39-e40. [PMID: 28750150 DOI: 10.1111/jdv.14486] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
22
|
Toxican : un outil à d’aide à la cotation des toxicités cutanées des traitements anticancéreux au quotidien. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Un cas de maladie de Darier traitée efficacement par alitrétinoïne et 5-fluoro-uracile topique. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Combinaison cyclophosphamide et propranolol dans l’angiosarcome métastatique : un cas. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
|
26
|
Pneumopathie d’hypersensibilité au nivolumab d’évolution fatale. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Étude de la survenue de métastases cérébrales sous traitement par ipilimumab de mélanomes métastatiques. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Détection de mutations de BRAF dans le plasma de patients atteints de mélanome métastatique. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Premier cas d’érythème polymorphe sous anti-PD-1 (nivolumab). Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol 2015; 30:250-7. [PMID: 26524690 DOI: 10.1111/jdv.13443] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 09/04/2015] [Indexed: 01/10/2023]
Abstract
BACKGROUND Vemurafenib, a BRAF inhibitor, is commonly associated with skin toxicity. The impact of severe forms is unknown. OBJECTIVE To determine the rate of permanent vemurafenib discontinuation due to grade 3-4 skin toxicity, features of these toxicities, their recurrence rate after a switch to dabrafenib and their impact on overall survival. METHODS Retrospective cohort study of 131 patients treated with vemurafenib for melanoma between November 2010 and December 2014. Data on skin toxicities, the need for vemurafenib adjustment and the impact of switching to dabrafenib were collected. Regarding survival analysis, a conditional landmark analysis was performed to correct lead-time bias. RESULTS Among the 131 vemurafenib-treated patients, 26% developed grade 3-4 skin toxicity. Forty-four percent of them permanently discontinued their treatment, mainly due to rash and classic skin adverse reactions (Steven-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms). Conversely, photosensitivity and carcinomas rarely required treatment adjustment. Grade 3-4 rashes were associated with clinical or biological abnormalities in 94% of patients. Among the 10 patients who subsequently switched to dabrafenib, skin toxicity recurred only in one patient. Overall survival was significantly prolonged in case of severe skin toxicity emerging within the first 4 (P = 0.014) and 8 weeks (P = 0.038) on vemurafenib, with only a trend at 12 weeks (P = 0.052). Median overall survival was also prolonged in case of severe rash. CONCLUSION In this study, vemurafenib was continued in 56% of patients with grade 3-4 skin toxicity, which was associated with prolonged overall survival when emerging within the first 4 and 8 weeks of treatment. While developing severe skin adverse reactions permanently contraindicates vemurafenib use, other rashes should lead to retreatment attempts with dose reduction. In case of recurrence, dabrafenib seems to be an interesting option. For other skin toxicities, including photosensitivity and cutaneous carcinoma, treatment adjustment is usually not needed.
Collapse
|
31
|
Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J Neurooncol 2015; 126:355-60. [PMID: 26511495 DOI: 10.1007/s11060-015-1977-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 10/25/2015] [Indexed: 11/30/2022]
Abstract
UNLABELLED Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy on brain metastases. OBJECTIVES To assess the development of brain metastases under ipilimumab and identify clinical, histological or evolving criteria related to the appearance of these metastases. A retrospective study was conducted in 52 patients treated with 4 cycles of ipilimumab 3 mg/kg every 3 weeks for unresectable stage III or stage IV melanoma between January 2011 and July 2013 in a Department of Dermato-Oncology. As no data has been find in the literature, the results were compared to our other cohort of patients treated with vemurafenib during the same period. Ten patients (21.7 %) developed brain metastases under ipilimumab in a median time of 6.58 months after treatment initiation. The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site. The median survival after diagnosis of brain metastases was of 2.5 months. There was no significant difference with vemurafenib-treated patients in terms of incidence rate of brain metastasis, time of development and survival after diagnosis of cerebral metastases. This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases.
Collapse
|
32
|
[Diagnostic pitfalls of solar urticaria]. Ann Dermatol Venereol 2015; 142:299-300. [PMID: 25813186 DOI: 10.1016/j.annder.2014.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 11/09/2014] [Accepted: 12/29/2014] [Indexed: 11/30/2022]
|
33
|
Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumors. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131:375-383. [DOI: 10.1016/j.anorl.2014.06.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2014] [Accepted: 06/17/2014] [Indexed: 12/31/2022]
|
34
|
Apparition rare d’un DRESS syndrome sous vémurafénib. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
P273: Dysgueusie et dénutrition au cours des traitements par le vismodegib : effet d’une prise en charge nutritionnelle. NUTR CLIN METAB 2014. [DOI: 10.1016/s0985-0562(14)70915-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Réponse spectaculaire d’un carcinome de Merkel sous imatinib. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Mélanomes vaginaux et vulvaires métastatiques : intérêt de l’ipilimumab ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
38
|
Quand les habits aident au diagnostic d’une photodermatose rare. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Acneiform rash: an unusual presentation of epithelioid haemangioma. J Eur Acad Dermatol Venereol 2014; 30:470-2. [PMID: 25376982 DOI: 10.1111/jdv.12852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol 2014; 29:1006-9. [PMID: 24980899 DOI: 10.1111/jdv.12526] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2014] [Accepted: 03/17/2014] [Indexed: 01/12/2023]
Abstract
BACKGROUND Basal cell carcinoma (BCC) is the most common cancer in humans. Vismodegib, a Hedgehog pathway inhibitor, has proved its effectiveness in treating non-resectable advanced BCC. AIM However, its action on squamous cell carcinoma (SCC) is unknown. We present three SCC cases developed into BCC in vismodegib-treated patients. MATERIAL AND METHODS We have described three cases of patients developing SCC during treatment by vismodegib for BCC. RESULTS Patient 1 was treated with vismodegib for five facial BCC. Due to the progression of one of the lesions at month 3 (M3), a biopsy was performed and showed SCC. Patient 2 was treated with vismodegib for a large facial BCC. A biopsy was performed at M2 on a BCC area not responding to treatment and showed SCC. Patient 3 was treated with vismodegib for a BCC on the nose. Due to vismodegib ineffectiveness, a biopsy was performed and showed SCC. DISCUSSION Two similar cases have been described in the literature. This could be due to the appearance of the squamous contingent of a metatypical BCC or to the squamous differentiation of stem cells through inhibition of the hedgehog pathway. CONCLUSION In practice, any dissociated response of a BCC to vismodegib should be biopsied.
Collapse
|
41
|
Autoimmune thyroiditis and isotretinoin: real association or coincidence? J Eur Acad Dermatol Venereol 2014; 30:125-6. [PMID: 24862460 DOI: 10.1111/jdv.12577] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Accepted: 04/30/2014] [Indexed: 11/30/2022]
|
42
|
Efficacité du vemurafenib chez deux patients atteints de mélanome métastatique BRAF discordant. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Efficacité spectaculaire du brentuximab vedotin dans deux cas de lymphome cutané T épidermotrope en impasse thérapeutique. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Dysgueusie et perte de poids sous vismodegib : intérêt d’une prise en charge nutritionnelle spécifique. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Predictive value of T-cell clone and CD13 antigen in parapsoriasis. J Eur Acad Dermatol Venereol 2013; 28:518-20. [PMID: 23859066 DOI: 10.1111/jdv.12212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2013] [Accepted: 06/12/2013] [Indexed: 11/29/2022]
|
46
|
Melanoma and rituximab: an incidental association? Dermatology 2013; 226:274-8. [PMID: 23941917 DOI: 10.1159/000350681] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Accepted: 03/11/2013] [Indexed: 11/19/2022] Open
Abstract
Rituximab is an anti-CD20 monoclonal antibody increasingly used in haematology and rheumatology, but also in internal medicine and dermatology. It has a good tolerance profile without known increased risk of cancer. We report a case of nodular melanoma with a 4.8 mm Breslow thickness that appeared after 2 years of rituximab in a 45-year-old patient with non-Hodgkin lymphoma. Fifteen additional rituximab-associated melanoma cases in 13 patients have been identified in the literature and in the EudraVigilance database. These patients were treated for various indications and had melanomas, often aggressive, initially diagnosed at a metastatic stage in 31% of cases. Our work raises the question of rituximab accountability in melanoma onset in these immunosuppressed patients. A dermatological monitoring seems necessary in patients treated with rituximab, especially in case of risk factors for melanoma. In case of individual melanoma history, the benefit/risk ratio of initiating rituximab therapy should be carefully assessed.
Collapse
|
47
|
Traitement du mycosis fongoïde par photothérapie dynamique : étude prospective. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Dix ans de traitement du lymphome cutané T épidermotrope par bexarotène. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Efficacité du vorinostat dans les lymphomes cutanés T réfractaires ou récidivant après traitement systémique. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Intérêt du traitement par TILs (Tumor-Infiltrating Lymphocytes) dans le mélanome métastatique. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|